(secondQuint)Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers.

 The number of patient is eighty-four.

 Patients were randomly assigned either a Bonviva tablet(150mg Ibandronate, qd) first, DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) Second or DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) first, Bonviva tablet(150mg Ibandronate, qd) second.

.

 Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers@highlight

The purpose of this study is compare the pharmacokinetic characteristics of DP-R206 (150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) and Bonviva (150mg Ibandronate, qd) after oral administration in healthy adult volunteers.

